Anzeige
Erschienen in:
01.05.2010 | Symposium: Current Issues in Knee Reconstruction
Midterm Assessment of Causes and Results of Revision Total Knee Arthroplasty
Erschienen in: Clinical Orthopaedics and Related Research® | Ausgabe 5/2010
Einloggen, um Zugang zu erhaltenAbstract
Background
There is limited information regarding revision total knee arthroplasty (TKA) with respect to etiology, outcome, and long-term survival comparing different implant types.
Questions/purposes
We compared patient outcomes, survivorship and modes of failure and the most common etiologic factors for rerevision between different revision implant types.
Methods
We retrospectively reviewed 349 cases of revision TKA in 343 patients whose mean age was 67.8 years. Three implant types were used: posterior stabilized, condylar constrained knee, and rotating hinge. The etiologies included infection (32.7%), aseptic loosening (14.9%), and polyethylene wear (12.3%). The minimum followup was 12 months (mean, 57.7 months; range, 12–120 months).
Results
The mean Knee Society scores were 89 (range, 48–94), 88.9 (range, 45–95), and 84 (range, 56–94) and the mean ranges of motion were 110.0° (range, 70°–125°), 106.1° (range, 70°–120°), and 111.7° (range, 85°–125°) for the posterior stabilized, condylar constrained knee, and rotating hinge types, respectively. The rotating hinge group had the highest satisfaction rates (88%). Overall 10-year survivorship was 90.6% with highest survivorship seen in the rotating hinge group. The most common causes for rerevision were infection (2.9% of our cohort), instability (1.7%), and aseptic loosening (1.4%). The mean overall time to rerevision was 69.9 months (range, 11–119 months).
Conclusions
In our experience periprosthetic infection is the most common cause of failure of both primary and revision TKA. Functional outcome and range of motion improve irrespective of revision implant type. The rotating hinge prosthesis provides patient satisfaction and survivorship similar to that of other implant types.
Level of Evidence
Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.